Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Bajetta E, et al. Among authors: carteni g. Cancer. 2006 Nov 15;107(10):2474-81. doi: 10.1002/cncr.22272. Cancer. 2006. PMID: 17054107 Free article. Clinical Trial.
Targeted therapy in the treatment of metastatic renal cell cancer.
Di Lorenzo G, Scagliarini S, Di Napoli M, Scognamiglio F, Rizzo M, Carteni' G. Di Lorenzo G, et al. Among authors: carteni g. Oncology. 2009;77 Suppl 1:122-31. doi: 10.1159/000258504. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130440 Review.
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G, Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S. D'Alterio C, et al. Among authors: carteni g. Curr Cancer Drug Targets. 2010 Nov;10(7):772-81. doi: 10.2174/156800910793605839. Curr Cancer Drug Targets. 2010. PMID: 20578990
Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. Gore ME, et al. Among authors: carteni g. Cancer. 2011 Feb 1;117(3):501-9. doi: 10.1002/cncr.25452. Epub 2010 Sep 22. Cancer. 2011. PMID: 20862748 Free article.
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Porta C, et al. Among authors: carteni g. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. BJU Int. 2011. PMID: 21599821
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S. D' Alterio C, et al. Among authors: carteni g. Curr Cancer Drug Targets. 2012 Jul;12(6):693-702. doi: 10.2174/156800912801784820. Curr Cancer Drug Targets. 2012. PMID: 22463589
140 results